PUBLIC LAW 100-607—NOV. 4, 1988

102 STAT. 3065

"(b) NOTICE TO SECRETARY AND TO ASSISTANT SECRETARY FOR
HEALTH.—The Administrator of the Alcohol, Drug Abuse, and
Mental Health Administration, the Director of the Centers for
Disease Control, the Commissioner of Food and Drugs, and the
Director of the National Institutes of Health, shall, respectively,
transmit to the Secretary and the Assistant Secretary for Health a
copy of each priority request made under this section by the agency
head involved. The copy shall be transmitted on the date on which
the priority request involved is made.

"(c) DEFINITION OF PRIORITY REQUEST.—For purposes of this sec-
tion, the term 'priority request' means any request that-
'll) is designated as a priority request by the Administrator of
the Alcohol, Drug Abuse, and Mental Health Administration,
the Director of the Centers for Disease Control, the Commis-
sioner of Food and Drugs, or the Director of the National
Institutes of Health; and

"(2)(A) is made to the Director of the Office of Personnel
Management for the allocation of personnel to carry out activi-
ties with respect to acquired immune deficiency syndrome; or
"(B) is made to the Administrator of General Services for
administrative support or space in carrying out such activities.

"SEC. 2304. ESTABLISHMENT OF CLINICAL RESEARCH REVIEW COM- 42 USC 300ce-3.

MITTEE.

"(a) IN GENERAL.—After consultation with the Commissioner of
Food and Drugs, the Secretary, acting through the Director of the
National Institute of Allergy and Infectious Diseases, shall establish
within such Institute an advisory committee to be known as the
AIDS Clinical Research Review Committee (hereafter in this section
referred to as the 'Committee').

"(b) COMPOSITION.—The Committee shall be composed of physi-
cians whose clinical practice includes a significant number of
patients with acquired immune deficiency syndrome.
"(c) DUTIES.—The Committee shall—

"(1) advise the Director of such Institute on appropriate
research activities to be undertaken with respect to clinical
treatment of such syndrome, including advice with respect to—
"(A) research on drugs for preventing or minimizing the
development of symptoms or conditions arising from infec-
tion with the etiologic agent for such syndrome; and

"(B) research on the effectiveness of treating such symp-
toms or conditions with drugs that—

"(i) are not approved by the Commissioner of Food
and Drugs for the purpose of treating such symptoms
or conditions; and

"(ii) are being utilized for such purpose by individ-
uals infected with such etiologic agent;

"(2XA) review ongoing publicly and privately supported re-
search on clinical treatment for acquired immune deficiency
syndrome, including research on drugs described in paragraph
(1); and

"(B) periodically issue, and make available to health care Reports.

professionals, reports describing and evaluating such research.

"(3) conduct studies and convene meetings for the purpose of

determining the recommendations among physicians in clinical

practice on clinical treatment of acquired immune deficiency